STEPHEN YENZEN LAI to Tumor Burden
This is a "connection" page, showing publications STEPHEN YENZEN LAI has written about Tumor Burden.
Connection Strength
0.402
-
Incompletely treated malignancies of the major salivary gland: Toward evidence-based care. Head Neck. 2018 08; 40(8):1630-1638.
Score: 0.100
-
Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head Neck. 2017 08; 39(8):1609-1620.
Score: 0.094
-
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res. 2011 Apr 15; 17(8):2281-91.
Score: 0.060
-
Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009 Dec 01; 75(5):1493-500.
Score: 0.054
-
Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid. 2018 08; 28(8):982-990.
Score: 0.025
-
Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. Radiother Oncol. 2017 08; 124(2):248-255.
Score: 0.024
-
HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance. Mol Cancer Res. 2011 Mar; 9(3):259-70.
Score: 0.015
-
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther. 2010 Jul; 9(7):2057-67.
Score: 0.015
-
MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul; 9(7):1968-76.
Score: 0.015